stockportfolio.pro
Aktis Oncology, Inc. (AKTS)
Healthcare · Biotechnology · NasdaqGS
Aktis Oncology, Inc. revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $1.49M | $6.50M |
| Gross profit | — | — | — | — |
| Net income | $-17.93M | $-28.64M | $-43.98M | $-63.73M |
| Net margin | — | — | -2957.6% | -980.9% |
Source: Aktis Oncology, Inc. SEC filings (10-K).
Explore 4 years of Aktis Oncology, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track AKTS in your portfolio →
Aktis Oncology, Inc. financial history by metric
About Aktis Oncology, Inc.
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.
Aktis Oncology, Inc. — frequently asked questions
What is Aktis Oncology, Inc.'s revenue?
Aktis Oncology, Inc. (AKTS) reported revenue of $6.50M for fiscal year 2025, up 336.9% from the prior year, according to its SEC filings.
Is Aktis Oncology, Inc. profitable?
No — AKTS reported a net loss of $-63.73M in fiscal 2025.
What is AKTS's P/E ratio?
Aktis Oncology, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Aktis Oncology, Inc. have?
As of fiscal year 2025, AKTS carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Aktis Oncology, Inc.'s market cap?
Aktis Oncology, Inc. (AKTS) has a market capitalization of about $1.03B, based on the latest data in our nightly-refreshed cache.
When does Aktis Oncology, Inc.'s fiscal year end?
AKTS's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Aktis Oncology, Inc.'s official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.